Biopharmaceutical leader in the development of treatments for rare diseases
Monitoring the implementation of the Patient Protection and Affordable Care Act, including provisions related to regulatory pathway for biosimilars and orphan drugs.
Education and outreach on treatment of rare diseases to Congressional staff.
Monitored deficit reduction initiatives related to enactment of an increase in the U.S. federal debt ceiling. P.L. 112-25 - The Budget Control Act of 2011 as it relates to proposals affecting reimbursement of Part B drugs. P.L. 112-25 - The Budget Control Act of 2011 as it relates to Medicare reimbursement for Part B drugs.
HCR - Health Issues MMM - Medicare/Medicaid
2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
W STRATEGIES, LLC
1455 Pennsylvania Avenue, NW, Suite 400, Washington, DC, 20004, US
DARREN WILLCOX DARREN WILLCOX